NYSE · Healthcare · Medical Distribution · USA
Accendra Health Inc is a micro cap company (market value under $300 million) in the Medical Distribution industry.
Accendra Health provides home healthcare equipment and medical supplies to patients through its brands Apria and Byram Healthcare. The company delivers products and services for diabetes, respiratory therapy, and sleep apnea treatment, generating revenues from Medicare, Medicaid, commercial insurers, and direct patient payments. It serves patients and healthcare providers through fee-for-service arrangements.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Accendra Health Inc stock.
No reliable verdict: intrinsic value $22.70 per share, market price $0.25 (as of 2026-10-30).
Discounting its cash flows would put the shares at $22.70: 91 times the price of $0.25. A gap that size says more about a model than about the market. It usually means heavy debt, where a small error in the value of the business becomes a large one in the value of the shares, or a business our method does not describe. We do not publish a verdict on this one.
Leak Score: 47/100 on 8 of 12 signals (On Watch).
17 more funds hold it; the full list is part of the paid plan.
All 11 Medical Distribution stocks
We do not publish a verdict on ACH. Discounting its cash flows would put the shares at $22.70: 91 times the price of $0.25. A gap that size says more about a model than about the market. It usually means heavy debt, where a small error in the value of the business becomes a large one in the value of the shares, or a business our method does not describe. We do not publish a verdict on this one.
We do not publish one (as of the 2026-10-30 close). Discounting its cash flows would put the shares at $22.70: 91 times the price of $0.25. A gap that size says more about a model than about the market. It usually means heavy debt, where a small error in the value of the business becomes a large one in the value of the shares, or a business our method does not describe. We do not publish a verdict on this one.
47 out of 100, which we rate "On Watch", on 8 of 12 value investing signals.